Navigation Links
Lupus Foundation of America Statement on Results for Clinical Study,of CellCept Released by Aspreva Pharmaceutical Company

Statement by Sandra C. Raymond, President & CEO of the Lupus Foundation of America, Inc.

WASHINGTON, June 27, 2007 /PRNewswire-USNewswire/ -- The Lupus Foundation of America, Inc. and more than 1.5 million Americans with lupus have been awaiting the preliminary findings of the Phase III clinical trials for CellCept(R), a potential treatment for lupus kidney disease being tested by Aspreva Pharmaceutical Company. Development of new treatments for lupus patients is critical because many of the drugs currently used to treat the disease are toxic and can cause serious medical complications or side effects, sometimes worse than the disease itself.

Preliminary data from the 24-week induction phase show that CellCept achieved results that are equivalent to those achieved with intravenous Cyclophosphamide (IVC), a chemotherapy which has been used to treat patients with lupus kidney disease (lupus nephritis) since the 1970s. However, while IVC has been referred to as the "standard of care" for treatment of lupus nephritis it has never been approved by the FDA as a treatment for lupus.

In order to meet the primary endpoint, the FDA required Aspreva Pharmaceutical Company to show that CellCept was superior in efficacy to IVC. The LFA contends that this bar was unreasonably set too high by the FDA. Equal efficacy and less severe side effects would be a compelling rationale for approving a drug for this underserved disease, which would be welcomed by people with lupus and their physicians. Furthermore, if more agents could be developed with less toxicity, there would be improved opportunities for combination therapies in the treatment of nephritis.

An additional concern is that if CellCept induces 52% remission and IVC induces the same percentage of remission, it may be that each is covering a different subset of the population. Thus having the alternative treatments available might be an important
'"/>




Page: 1 2

Related medicine technology :

1. Aspreva and Roche Announce Preliminary Results for Phase III Study Evaluating CellCept in Lupus Nephritis
2. Human Genome Sciences Reports That a Phase 2 Study of LymphoStat-B Showed Significant Reductions in Disease Activity in Patients with Active Systemic Lupus Erythematosus
3. Cellerant Therapeutics Reversed Autoimmune Disease in Lupus Mice with Transplant of Purified Donor Blood Stem Cells
4. La Jolla Pharmaceutical Provides Update on Interim Antibody Results From Riquent Lupus Phase 3 Trial
5. La Jolla Pharmaceutical Announces Positive Interim Antibody Results From Riquent Lupus Phase 3 Trial
6. The International Myeloma Foundation Says Data Reported at a Global Medical Meeting in Greece Demonstrates Improved Survival for a Wide Range of Myeloma Patients
7. The Christopher and Dana Reeve Foundation Expresses Disappointment Over President Bushs Veto of the Stem Cell Research Enhancement Act
8. Hypertension Education Foundation Survey Results Announced At American Society For Hypertension Annual Meeting Suggests Improved Control Of High Blood Pressure, But Misconceptions Still Exist
9. The International Myeloma Foundation Reports Positive Shift In Treatment Paradigm For Patients
10. Research Supported by Samuel Waxman Cancer Research Foundation Discovers Mode of Action of Arsenic-Based Drugs in Destroying Cancer Cells
11. The International Myeloma Foundation Says New Clinical Trial Results Could Improve Survival While Reducing Side Effects For Many Patients
Post Your Comments:
(Date:5/23/2013)... -- Hearing health affects a man,s lifestyle, and if he ... professionally engaged, he should address any hearing loss he may ... Better Hearing Institute (BHI) is delivering to men around ... , which leads up to and includes Father,s Day. This ... June 16. To help men address their ...
(Date:5/23/2013)... -- A recently published clinical study conducted at TOPS Comprehensive ... demonstrates that 3D mammography (breast tomosynthesis) significantly reduces unnecessary ... The study, "Implementation of Breast Tomosynthesis in a Routine ... Stephen L. Rose , MD, and published ... of Roentgenology (AJR). The AJR is the scientific ...
(Date:5/23/2013)... Bio-Holdings Ltd. (TASE: HDST, OTC: HADSY), a publicly ... property developed and owned by Hadassah University Hospital, ... center, today announced that its portfolio company, Cell ... Israeli Ministry of Industry and Commerce, Office of ... and advance clinical trials. Cell Cure,s development budget ...
Breaking Medicine Technology:Men Who Want to Stay Active, Feel Younger, and Remain Socially and Professionally Engaged Should Address Hearing Loss, BHI Advises 2Men Who Want to Stay Active, Feel Younger, and Remain Socially and Professionally Engaged Should Address Hearing Loss, BHI Advises 3Men Who Want to Stay Active, Feel Younger, and Remain Socially and Professionally Engaged Should Address Hearing Loss, BHI Advises 4First Large-Scale U.S. Study Validates the Benefits of 3D Mammography (Breast Tomosynthesis) Exams 2First Large-Scale U.S. Study Validates the Benefits of 3D Mammography (Breast Tomosynthesis) Exams 3Hadasit Bio-Holdings Ltd. Portfolio Company - Cell Cure Neurosciences Ltd. Received Additional Government Support 2
... blood,pressure, reduces blood flow in the brains of adults ... at the annual meeting of,the Radiological Society of North ... of Alzheimer,s disease, our study,shows that it is another ... effects of the disease," said study co-author Cyrus Raji, ...
... 28 Immunosyn,Corporation (OTC Bulletin Board: IMYN) today ... MHRA to import base material,and manufacture SF-1019 for ... for which Immunosyn holds the exclusive license for,worldwide ... Regulatory Agency," more,commonly known as the MHRA, functions ...
Cached Medicine Technology:High Blood Pressure May Heighten Effects of Alzheimer's Disease 2Immunosyn Announces Biozyme Lab's Receipt of MHRA Manufacturing License Approval in Europe for the Biopharmaceutical SF-1019 2Immunosyn Announces Biozyme Lab's Receipt of MHRA Manufacturing License Approval in Europe for the Biopharmaceutical SF-1019 3
(Date:5/24/2013)... E-Dentists.com has announced the launch of their new ... a leading medical Internet marketing agency. , ... focus on providing dentists the help they need to ... keywords. The dental SEO analysis covers a full analysis ... their competitors are doing right. The goal is to ...
(Date:5/24/2013)... Started in 1982, AMTC’s SHINE event is a ... AMTC’s 31st anniversary. SHINE is a ministry run by three ... and her daughter, Carey Lewis Arban. , This summer’s SHINE ... music professionals including the New York Film Academy, The New ... kings of Hollywood and Christian casting directors. They seek ...
(Date:5/24/2013)... Utah (PRWEB) May 24, 2013 Amirsys ... with exciting new enhancements for instructors and students. Instructors ... more focused through personalize learning plan templates, targeted reading ... release provides 500 new assessment questions, 5,000 searchable anatomy ... notes. , AnatomyOne 2.0 is the first ...
(Date:5/24/2013)... Dwell Media LLC announces ... Executive Vice President of Digital for Dwell Media. At ... a large portion of Yahoo's global media business. At ... a fully-integrated commerce unit to launch in 2014. Huff ... content for leading firms in Silicon Valley. Dwell, which ...
(Date:5/24/2013)... (HealthDay News) -- Low-income, minority parents have more ... are more open to vaccinating their daughters against ... new study contends. Conversely, white, middle-class parents ... their daughters, according to researchers from the Boston ... will get an HPV-related cancer each year, many ...
Breaking Medicine News(10 mins):Health News:Dental SEO Analysis Launched by E-Dentists.com in Partnership with JD Media Surge 2Health News:AMTC’s Summer SHINE Event Coming to Orlando’s Luxurious Gaylord Palms July 2-7, 2013 2Health News:Amirsys AnatomyOne 2.0 Delivers Personalized Learning Plans 2Health News:Yahoo Commerce Head Joins Leadership at Dwell Media 2Health News:Low-Income, Minority Parents More Open to HPV Vaccine for Girls, Study Says 2
... PCYC ) today announced that it will ... 2008 financial results and achievements on,Thursday, April 24, ... To participate in the conference call, please ... callers and reference,conference passcode, 43624853. To access the ...
... in addressing the problem, ALEXANDRIA, Va., April ... the only national organization,representing physician assistants (PA) in ... in on the challenges outlined in the,Institute of ... workforce,and aging baby boomers. There are an estimated ...
... the male hormone in the morning made more money , , ... Britain finds that financial traders who wake up with high ... money that day, probably because they feel more daring. ... the stress hormone cortisol tend to be more cautious. , ...
... DETROIT, April 14 A unique global conference,focusing ... Detroit June 8 - 10,2009. The HealthQuake Summit ... world to gather and explore the ongoing and ... areas of business, policy, and,science/technology that will make ...
... Passover, ATLANTA, April 14 As Americans travel ... for Disease Control,and Prevention advises all travelers to ensure ... measles outbreak in Israel., Since September, more than ... about 700 cases in the cities of Jerusalem and ...
... half the risk of needing to start treatment , , ... levels of the antioxidant urate in their blood appear to ... lower levels do, a new report says. , The findings, ... Neurology , support early laboratory studies about urate,s protective qualities ...
Cached Medicine News:Health News:Health Care Workforce Experts Available to Comment on IOM Report on Aging Baby Boomers and Impending Medical System Crisis 2Health News:Testosterone Levels Among Financial Traders Affect Performance 2Health News:Testosterone Levels Among Financial Traders Affect Performance 3Health News:CDC Urges Travelers to Israel to Protect Themselves from Measles 2Health News:Elevated Urate Levels May Slow Parkinson's in Men 2
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
Medicine Products: